RefinedOrganoids
Website RefinedOrganoids is a research-stage biotechnology company developing patient-derived organoid models for precision oncology. We are building next-generation tools to guide cancer treatment decisions.
Website RefinedOrganoids is a research-stage biotechnology company developing patient-derived organoid models for precision oncology. We are building next-generation tools to guide cancer treatment decisions.
Website Integrated Hematopathology and Molecular Oncology Diagnostic Services
Website Trilis Bioscience is developing a next-generation molecular detection platform that moves beyond conventional protein quantification by directly measuring functionally relevant post-translational modifications (PTMs) on specific protein targets within a single assay. Our proprietary co-recognition proximity architecture integrates AI-enabled minibinder engineering with oligonucleotide-based molecular logic to achieve highly specific, scalable, and multiplexed detection at the…
Website Exsera BioLabs is a CAP/CLIA-certified niche laboratory specializing in autoimmune and complement testing, all conducted in compliance with FDA GxPs. They provide esoteric testing to support diagnostics and biomarker translation, with a strong focus on both autoimmune diseases and complement-related conditions. Their collaborations with researchers, biotech, and pharmaceutical companies help advance scientific discoveries and…
Website OXcan (Oxford Cancer Analytics) is revolutionizing cancer detection starting from lung cancer by developing blood-based diagnostics for cancer identification, especially at the early stage, when treatment with curative intent may still be possible.
Website Cobio Diagnostics is a life sciences biotechnology company dedicated to the development and commercialization of rapid, next-generation, phage-amplified diagnostics for bacterial ID and phenotypic detection of antibiotic resistance.
Website Rapid, inexpensive, universal, on-site, pan-cancer monitoring of therapy effectiveness; ultimately an inexpensive, universal, pan-cancer screening test. Early identification of hyper-progressive disease or any inactive therapy and switching to an effective therapy can be lifesaving!
Website Starlyte Bio aims to push diagnostic technology into the next generation by illuminating the whole picture across diseases using the full chromatin structure that defines the disease state. This will provide insights into health and disease like never before.
Website Vega Surgical combines the efficacy of the operating room with the efficiency of a bedside procedure, significantly decreasing cost and, more importantly, improving patient outcomes. Vega will treat what will soon be the most common cranial neurosurgical disorder, Chronic Subdural Hematomas (CSDH), with the Xcape port and Axis Drill. Today, CSDHs are treated in…
Website Vitan-Biotech specializes in the development and commercialization of breakthrough life science instrumentation, novel biosensing systems, and diagnostic devices. Vitan is developing novel cancer diagnostic devices, platforms for glycan biomarker discovery, and disposable biosensors for pathogen detection, including assay development services: Biochips for detecting multiple serum cytokines and cancer biomarkers; Point-of-care devices for Circulating Tumor…

Fitzsimons Innovation Community is an integrated urban campus where health and life sciences companies of all sizes work on their next big things. Our customized workspace, collaborative campus, and proximity to one of the top health systems and medical schools in the country make our community the perfect place to put down roots and get to work.
Move-In Ready Lab Space

12635 E Montview Blvd
Aurora, CO 80045
97,000 square feet

12705 E Montview Blvd
Aurora, CO 80045
106,000 square feet

2115 N Scranton St
Aurora, CO 80045
117,000 square feet

2251 N Revere St
Aurora, CO 80045
90,000 square feet ready for tenant improvements
Growth Opportunities

Fifty sprawling acres of additional space primed for ultra-custom, made-to-order facility development.

Fitzsimons Innovation Community and University of Colorado Anschutz Medical Campus working together.
Relationships that help you thrive.
Featured
Innovation does not stand still at Fitzsimons Innovation Community – and in 2025, the momentum was unmistakable. We are proud to announce the release of our 2025 Annual Innovation Report, a comprehensive look at the discoveries, partnerships, investments and infrastructure advancements shaping one of the nation’s most dynamic health innovation districts.